IQVIA is set to report fourth-quarter 2025 results on February 5, with consensus estimates forecasting revenues of $4.20 billion, up 7.2% year-over-year, driven by strength in the Contract Sales & Medical Solutions segment. Analysts project adjusted EPS of $2.10, a 9% increase from $1.93 a year earlier, reflecting operating leverage and ongoing cost-efficiency programs. Management has signaled that foreign currency headwinds will be a mid-single-digit drag on reported growth, while acquisitions completed in 2025 are expected to contribute approximately $150 million in incremental revenue for the quarter.

Beyond top-line and EPS, Wall Street surveys anticipate an adjusted EBITDA margin of 17.8% (versus 17.2% in Q4 2024), underpinned by higher utilization in the Real-World Evidence business and productivity gains in site management. Consensus forecasts call for free cash flow of $1.05 billion for the quarter, up from $950 million year-over-year, supporting a net leverage ratio of 2.5x at December 31. Order backlog across Clinical Development and Commercial offerings is estimated at $29 billion, reflecting an 8% increase over Q4 2024 and providing revenue visibility into mid-2026.